Bridgeway Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Bridgeway Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,874	Closed	-$22.4K	–	1189
2024 Q4	$22.4K	Sell	31,874 -44,826	-58%	-$22.2K	﹤0.01%	1182
2024 Q3	$35.9K	Hold	76,700	–	–	﹤0.01%	1231
2024 Q2	$127K	Hold	76,700	–	–	﹤0.01%	1137
2024 Q1	$140K	Sell	76,700 -14,500	-16%	-$29.9K	﹤0.01%	1168
2023 Q4	$169K	Buy	91,200 +25,000	+38%	+$33.1K	﹤0.01%	1170
2023 Q3	$95.3K	Hold	66,200	–	–	﹤0.01%	1238
2023 Q2	$121K	Hold	66,200	–	–	﹤0.01%	1227
2023 Q1	$131K	Hold	66,200	–	–	﹤0.01%	1183
2022 Q4	$139K	Hold	66,200	–	–	﹤0.01%	1166
2022 Q3	$126K	Hold	66,200	–	–	﹤0.01%	1232
2022 Q2	$141K	Sell	66,200 -10,000	-13%	-$25.8K	﹤0.01%	1160
2022 Q1	$206K	Buy	+76,200	New	+$294K	﹤0.01%	1168

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bridgeway Capital Management's CGTX Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Cognition Therapeutics (CGTX) in Q1 2025, closing a stake of 31,874 shares — an estimated $22.4K sold.

Bridgeway Capital Management first reported a position in CGTX in Q1 2022 and held it in 12 quarters. The position peaked at $206K in Q1 2022. 51 funds tracked by Wall St. Rank hold CGTX as of Q1 2025.

Bridgeway Capital Management reported no remaining Cognition Therapeutics position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 31,874 Cognition Therapeutics shares in Q1 2025, an estimated $22.4K.
Bridgeway Capital Management first reported a position in Cognition Therapeutics in Q1 2022 and held it in 12 quarters.
Bridgeway Capital Management's Cognition Therapeutics position peaked at $206K in Q1 2022.
51 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.